The price of Ascendis Pharma A/S (NASDAQ:ASND) shares last traded on Wall Street fell -1.13% to $122.39.
Based on available information, 16 analysts follow Ascendis Pharma A/S (NASDAQ:ASND). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $190.36 and a low of $88.66, we find $152.79. Given the previous closing price of $123.79, this indicates a potential upside of 23.43 percent. ASND stock price is now 2.45% away from the 50-day moving average and 19.13% away from the 200-day moving average. The market capitalization of the company currently stands at $6.89B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 1 rate the stock a hold while 15 rate it a buy. Brokers who have rated the stock have averaged $151.28 as their price target over the next twelve months.
With the price target of $174, Goldman recently initiated with Buy rating for Ascendis Pharma A/S (NASDAQ: ASND)., while ‘Wedbush’ rates the stock as ‘Outperform’.
A total of 0.06% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ASND stock. A new stake in Ascendis Pharma A/S shares was purchased by T. ROWE PRICE INVESTMENT MANAGEMENT, INC. during the first quarter worth $248,719,000. DEEP TRACK CAPITAL, LP invested $97,912,000 in shares of ASND during the first quarter. In the first quarter, POINT72 ASSET MANAGEMENT, L.P. acquired a new stake in Ascendis Pharma A/S valued at approximately $47,022,000. LOGOS GLOBAL MANAGEMENT LP acquired a new stake in ASND for approximately $30,598,000. CIBC ASSET MANAGEMENT INC purchased a new stake in ASND valued at around $15,796,000 in the second quarter.
A candlestick chart of Ascendis Pharma A/S (NASDAQ: ASND) showed a price of $123.42 on Tuesday morning. During the past 12 months, Ascendis Pharma A/S has had a low of $61.58 and a high of $134.52. As of last week, the company has a debt-to-equity ratio of 1.23, a current ratio of 7.60, and a quick ratio of 6.80. The fifty day moving average price for ASND is $119.46 and a two-hundred day moving average price translates $102.73 for the stock.
The latest earnings results from Ascendis Pharma A/S (NASDAQ: ASND) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$1.44, beating analysts’ expectations of -$2.1 by 0.66. This compares to -$1.73 EPS in the same period last year. The company reported revenue of $15.4 million for the quarter, compared to $1.31 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1072.89 percent. For the current quarter, analysts expect ASND to generate $8.96M in revenue.
Ascendis Pharma A/S(ASND) Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
